A Phase Ib,Open,Mono-center,Dose-escalation,Tolerability and Pharmacokinetic Study of Recombinant Humanized Anti-PD-1 mAb for Injection in Combination With Axitinib in Patients With Advanced Kidney Cancer and Melanoma
Latest Information Update: 05 Sep 2022
At a glance
- Drugs Toripalimab (Primary) ; Axitinib
- Indications Malignant melanoma; Renal cancer
- Focus Adverse reactions
- Sponsors Shanghai Junshi Biosciences
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 12 Aug 2019 Results (n=33 patients with advanced mucosal melanoma) published in the Journal of Clinical Oncology
- 07 Mar 2019 Planned End Date changed from 1 Feb 2021 to 1 Dec 2020.